COVID-19 Outpatient Therapeutics - Use and Distribution Information							
Туре	Name	Indication ¹					Distribution/Access Note that all state-distributed
		PrEP	Treatment	PEP	Formulation ²	Pediatric Use	therapeutics are currently available in limited quantities
monoclonal antibody	bamlanivimab/ etesevimab		V	~	IV	All ages	 Available in limited quantities Providers can request through REDCap³ Due to lack of effectiveness against omicron, may no longer be available soon
	casirivimab/ imdevimab (REGEN-COV)		V	V	IV, SQ	≥12 years	 Available in limited quantities Providers can request through REDCap³ Due to lack of effectiveness against omicron, may no longer be available soon
	sotrovimab		V		IV	. 42	 Distributed by CDPHE; allocation numbers determined by region Providers can request through REDCap³ Provider enrollment: cdphe.commentsoepr@state.co.us
	Evusheld (tixagevimab/ cilgavimab)	V			IM	≥12 years ≥40 kg	 Distributed by CDPHE Ordering through Tiberius¹ Ordering started with transplant centers; now expanding to other hospitals/healthcare systems
antiviral	molnupiravir		V		PO	none	 Distributed by CDPHE Allocations currently being delivered to
	Paxlovid (nirmatrelvir/ ritonavir)		V		РО	≥12 years ≥40 kg	 Allocations currently being delivered to hospitals/health systems and HRSA sites Ordering requests through HPOP⁵
	remdesivir ⁶		V		IV	≥12 years ≥40 kg	Not distributed by CDPHE

¹PrEP = pre-exposure prophylaxis; PEP = post-exposure prophylaxis

²IV = intravenous; SQ = subcutaneous; IM = intramuscular; PO = oral

³REDCap order form: https://cdphe.redcap.state.co.us/surveys/?s=LJWJ8E8JXLE4DHXN; regional allocation will determine availability

https://protect-ows.hhs.gov/multipass/login/all

https://docs.oracle.com/en/industries/health-sciences/vpop-provider/vpopu/get-started-oracle-vpop-provider-portal.html

⁶FDA approved for inpatient use; outpatient use is an off-label indication